1. EU SmPC
  2. ADVERSE EVENT REPORTING
TAGRISSO® (osimertinib)
  • Home
  • Early Stage Unmet Need
  • ADAURA
  • FLAURA
  • Safety
  • MOA
  • Dosing
  • AURA3
  • Resources
    • AstraZeneca Global Corporate Site
    • Privacy Notice
    • Site Map
    • Legal Statement
    • Cookies
    • Site Map
    • Site Map
    • EU SmPC
    • Adverse Event Reporting
    • Contact Us
    • AstraZeneca Global Corporate Site
    • Privacy Notice
    • Legal Statement
    • Cookies
    • Site Map
    • Site Map
    • EU SmPC
    • Adverse Event Reporting
    • Contact Us

This product information is intended for non-US and non-UK Healthcare Professionals only.

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2021 AstraZeneca. All rights reserved.

Date of Preparation: July 2021 VEEVA ID: Z4-31687 

AstraZeneca